Sponsored by
NanO2 is an investigational therapy being developed by NuvOx for newly diagnosed glioblastoma (GBM). It helps deliver oxygen into low-oxygen (hypoxic) tumor regions, making radiation more effective. It's given intravenously (just before each radiation session). The ongoing Phase IIb RESTORE trial for this therapy completed enrollment of 87 patients last month, and the company was recently awarded NIH/NCI funding to support advanced liquid biopsy work within the Phase IIb trial. We're glad to see this therapy advancing and hope to see positive results from the RESTORE trial within the next year.